Bleomycin Sulfate interactions
Checked as Bleomycin in this data source.
Full monograph for Bleomycin SulfateCheck it against another medicine
Medicines
179 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Thalidomide | Major | Synergy | Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism… | 20 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Bacitracin Zinc + Polymyxin B Sulfate | Moderate | Synergy | The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.2 documented mechanisms | 2 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Bendamustine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Capecitabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Carmustine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Ceftazidime + Avibactam | Moderate | Synergy | The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly… | 2 sources — open the full entry |
| Ceftazidime Pentahydrate | Moderate | Synergy | The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly… | 2 sources — open the full entry |
| Chlorambucil | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Chloramphenicol (Ophthalmic) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Cisplatin | Moderate | Synergy | The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly… | 2 sources — open the full entry |
| Colistimethate Sodium | Moderate | Synergy | The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. | 2 sources — open the full entry |
| Cyclophosphamide | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Cytarabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Dacarbazine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Daunorubicin | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Decitabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Denosumab | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy · Unknown | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…2 documented mechanisms | 8 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Moderate | Synergy · Unknown | The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.2 documented mechanisms | 2 sources — open the full entry |
| Digoxin | Moderate | Absorption | The use of some antineoplastic agents has been associated with decreased gastrointestinal absorption of digoxin. The suspected mechanism is alteration of the… | 7 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIB | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Diroximel Fumarate | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may… | 1 sources — open the full entry |
| Docetaxel Trihydrate | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Doxorubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Doxorubicin Hydrochloride Liposome | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Epirubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Etoposide | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Filgrastim | Moderate | Antagonism | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given… | 4 sources — open the full entry |
| Fludarabine Phosphate | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Fluorouracil | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Fosphenytoin Sodium | Moderate | Others | Cases have been reported in which patients receiving chemotherapy have experienced markedly reduced plasma phenytoin concentrations and seizures. Other… | 24 sources — open the full entry |
| Ganciclovir | Moderate | Synergy | The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or… | 7 sources — open the full entry |
Conditions
Conditions in which Bleomycin Sulfate needs care, as documented in this source.
Kidney Diseases
MajorBleomycin is primarily eliminated by the kidney. Approximately 60% to 70% of bleomycin is excreted in the urine as active drug. Moderate renal failure reduces elimination to < 20% of the drug. Extreme caution should be exercised when administering bleomycin in patients with existing or predisposition to significantly compromised renal function. Close clinical monitoring of renal function is recommended.
3 sources
- McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR "Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency." Cancer 60 (1987): 2617-20
- Bennett WM, Pastore L, Houghton DC "Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure." Cancer Treat Rep 64 (1980): 921-4
- "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb (2001):
Pulmonary Fibrosis
MajorPulmonary pneumonitis occurs in 10% of patients during bleomycin therapy and 1% progress to pulmonary fibrosis and death. Although pulmonary toxicity is age and dose related, occurring primarily in patients over 70 years of age and in those receiving a total dose > 400 units, it has occurred in younger patients at a lower dose. Extreme caution should be exercised when administering bleomycin in patients with compromised pulmonary function. Patients should be instructed to immediately report symptoms of dyspnea, cough, or congestion. Close clinical monitoring of pulmonary function is recommended.
9 sources
- Wolkowicz J, Sturgeon J, Rawji M, Chan CK "Bleomycin-induced pulmonary function abnormalities." Chest 101 (1992): 97-101
- Hartmann LC, Frytak S, Richardson RL, Coles DT, Cupps RE "Life-threatening bleomycin pulmonary toxicity with ultimate reversibility." Chest 98 (1990): 497-9
- Brown WG, Hasan FM, Barbee RA "Reversibility of severe bleomycin-induced pneumonitis." JAMA 239 (1978): 2012-4
- Bechard DE, Fairman RP, DeBlois GG, Via CT "Fatal pulmonary fibrosis from low-dose bleomycin therapy." South Med J 80 (1987): 646-9
- Jones AW "Bleomycin lung damage: the pathology and nature of the lesion." Br J Dis Chest 72 (1978): 321-6
- Doll DC "Fatal pneumothorax associated with bleomycin-induced pulmonary fibrosis." Cancer Chemother Pharmacol 17 (1986): 294-5
- Zucker PK, Khouri NF, Rosenshein NB "Bleomycin-induced pulmonary nodules: a variant of bleomycin pulmonary toxicity." Gynecol Oncol 28 (1987): 284-91
- Dalgleish AG, Woods RL, Levi JA "Bleomycin pulmonary toxicity: its relationship to renal dysfunction." Med Pediatr Oncol 12 (1984): 313-7
Show all 9 sourcesShow fewer sources
- "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb (2001):
Hepatic Insufficiency
ModerateThe effect of hepatic insufficiency on the pharmacokinetics of bleomycin has not been evaluated. However, hepatic toxicity, beginning as a deterioration in liver function tests, has been reported. These toxicities may occur at any time after initiation of therapy. Caution and monitoring is advised if bleomycin is used in patients with liver impairment.
1 source
- "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb (2001):
Therapeutic duplication
Drug classes that overlap with Bleomycin Sulfate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antineoplastic antibiotics
The recommended maximum number of medicines in the 'antineoplastic antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antineoplastic antibiotics' category.
Example product in the source data (US market): Vyxeos